

Title Page

Risk factors associated with morbidity and mortality outcomes of COVID-19 patients on the 14th and 28th day of the disease course: a retrospective cohort study in Bangladesh

M.Z. Islam^{1*}, B.K. Riaz², ANMS Islam², F. Khanam³, J. Akhter⁴, R. Choudhury⁴,
N. Farhana⁴, N.A. Jahan⁵, M.J. Uddin⁴, S.S. Efa¹

¹ *Department of Community Medicine, National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka-1212, Bangladesh.*

² *Department of Public Health and Hospital Administration, National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka-1212, Bangladesh.*

³ *Department of Parasitology, National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka-1212, Bangladesh.*

⁴ *Department of Microbiology and Mycology, National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka-1212, Bangladesh.*

⁵ *Department of Nutrition and Biochemistry, National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka-1212, Bangladesh*

The work is attributed to the Department of Community Medicine, National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka-1212, Bangladesh.

Disclaimers: The authors have none to declare

***Corresponding author:** Md. Ziaul Islam, PhD. Head, Department of Community Medicine, National Institute of Preventive and Social Medicine, Mohakhali, Dhaka-1212, Bangladesh.

Fax: (+88) 2989 8798. Cell: +8801726693778.

e-mail: dr.ziaul.islam@gmail.com; ziauliph67@yahoo.com

Running Title: Risk factors and outcomes of COVID-19

Risk factors associated with morbidity and mortality outcomes of COVID-19 patients on the 14th and 28th day of the disease course: a retrospective cohort study in Bangladesh

Original Research Article

Summary

Diverse risk factors intercede the outcomes of COVID-19. We conducted this retrospective cohort study to identify the risk factors associated with morbidity and mortality outcomes with a cohort of 1016 COVID-19 patients diagnosed in May 2020. Data were collected by telephone-interview and reviewing records using a questionnaire and checklist. Morbidity (64.4% Vs. 6.0%) and mortality (2.3% Vs. 2.5%) outcomes varied between the 14th and 28th day. Morbidity risk factors included chronic obstructive pulmonary disease (COPD) (RR=1.19, RR=2.68) both on the 14th and 18th day while elderly (AOR=2.56) and smokeless tobacco (SLT) (AOR=2.17) on the 28th day. Mortality risk factors included elderly (AOR=10.14), COPD (RR=5.93), and SLT (AOR=2.25) on the 14th day, and elderly (AOR=24.37) and COPD (RR=2.72) on the 28th day. The morbidity risk was higher with chronic kidney disease (CKD) (RR=3.33) and chronic liver disease (CLD) (RR=3.99) on the 28th day. The mortality risk was higher with coronary heart disease (RR=4.54) and CLD (RR=9.66) on the 14th while with diabetes mellitus (RR=3.08, RR=2.08), hypertension (RR=3.14, RR=2.30), CKD (RR=8.97, RR=2.71), and malignant diseases (RR=10.29) on both 14th and 28th day. We must espouse program interventions considering the morbidity and mortality risk factors to condense the aggressive outcomes of COVID-19.

Key words: Cohort, COVID-19 patients, Risk factors, Morbidity, Mortality and Outcomes.

Introduction

A newly emergent coronavirus (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) was first documented in Wuhan City, Hubei Province, China in December 2019 as an outbreak of pneumonia of mysterious cause [1]. Based on phylogeny, taxonomy, and established practice, on 11 February 2020, the World Health Organization (WHO) named the disease as COVID-19 [2]. WHO declared COVID-19 as a global emergency on 30 January 2020 [3] and as pandemic on 11 March 2020 [4]. Globally 213 countries are confronting the grave consequences of the ongoing COVID-19 pandemic. The situation is sprouting rapidly with increasing case counts and deaths worldwide [5]. In this course, Bangladesh is also confronting the tolls of morbidity and mortality posed by this highly infectious disease with community transmission across the country.

The clinical spectrum of COVID-19 appears to be in a wide range, encompassing asymptomatic infection, mild (40%) or moderate (40%) disease, severe disease (15%) that requires oxygen support, and only 5% critical disease [1]. The incubation period of COVID-19 infection is around 5.2 days and the period from the onset of symptoms to death ranges from 6 to 41 days with a median of 14 days [6]. A study conducted in Wuhan of China found that increased age and various comorbidities like hypertension and diabetes mellitus (DM) were associated with the severity of COVID-19. But the study didn't identify the tobacco use and chronic obstructive pulmonary disease (COPD) as the risk factors for COVID-19 [7].

Another study in China found that nearly half of the patients had comorbidity where hypertension was the most common followed by DM and coronary heart disease (CHD). The study also established the association between increased age and death of the COVID-19 patients [8]. Another study showed that severe patients were older and had comorbidities including

hypertension (30.0%), diabetes mellitus (12.1%), and cardiovascular diseases. The median age was 64 years in severe cases and 51.5 years in non-severe cases [7]. The presence of any comorbidity was more common among the severe patients than those having a mild or moderate disease (38.7% vs. 21.0%) with a similar exposure history between the two groups of disease severity [9].

Widespread shreds of evidence have emphasized the harmful impact of tobacco use possibly related to adverse outcomes of COVID-19. One of the leading studies conducted in the Wuhan city of China found higher percentages of current and former tobacco users among the patients that needed ICU support, mechanical ventilation or who had died, and a higher prevalence of smoking among the severe cases [10].

A study conducted on outcomes of the COVID-19 patients found that non-survivors were more often older and men, and they had a higher prevalence of DM, hyperlipidemia, and CHDs. The history of current tobacco use and having COPD was more among the non-survivors [11].

However, the pandemic is still under progression, diverse risk factors influence the outcomes of COVID-19, but relevant data and studies are very scarce in Bangladesh. Therefore, it is irrefutably obligatory to determine the risk factors to avert the aggressive consequences of COVID-19 patients. Based on these realities, in this particular study, we aimed to identify the risk factors associated with morbidity and mortality outcomes of COVID-19 patients.

Methods:

Study setting, design, and population

This observational retrospective cohort study was conducted on the National Institute of Preventive and Social Medicine (NIPSOM), Dhaka, Bangladesh during the period from March to June 2020. The study enrolled a cohort of laboratory-confirmed 1016 COVID-19 (SARS-CoV-2)

patients diagnosed at the central laboratory of NIPSOM, Dhaka. The NIPSOM is the apex public health institute holding the central laboratory designated for COVID-19 diagnosis, approved by the Ministry of Health and Family Warfare, the government of Bangladesh. The participant who had no contact telephone/cell phone number; who didn't respond to a phone call on three (03) separate occasions within 28 days of diagnosis; who were unwilling; and who had incomplete interview were excluded from the study.

Cohort:

The cohort comprised of all the laboratory-confirmed COVID-19 patients, who were diagnosed at the central laboratory of NIPSOM during the period from 01 to 30 May 2020 by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasopharyngeal (NP) / Oropharyngeal (OP) / Nasal swab.

Exposures:

The exposures were the risk factors linked with the morbidity and mortality outcomes of the COVID-19 patients, which included baseline characteristics, comorbidity, and tobacco use.

Outcomes:

Both morbidity (cure/not-cured) and mortality (survivors/non-survivor) outcomes of the COVID-19 were identified and compared between exposed and non-exposed groups on the 14th and 28th day of the disease course.

Sample size and sampling

Initially, all the 1187 laboratory-confirmed COVID-19 patients diagnosed in May 2020 were selected as the study cohort. Finally, 1016 COVID-19 patients were enrolled as the study samples considering the selection criteria and single-centered cluster sampling technique. All the COVID-19 patients formed the sampling frame and each patient was a sampling unit.

Data collection and analysis

Data were collected by telephone interview and medical records review using a semi-structured questionnaire and checklist respectively. Each telephone interview session was recorded by a digital recorder to ensure the validity of data. The data collection instruments were pretested on the COVID-19 patients diagnosed in April 2020 and accordingly necessary corrections were performed for finalization. Participation of the COVID-19 patients was voluntary and informed consent was obtained from each participant before data collection. In case of non-survivor, data were collected from the eligible family member of the respective non-survivor. Measures were taken to ensure data quality; inconsistency and irrelevance of data were checked and corrected. Data were analysed using SPSS STATISTICS (Version 25.0, IBM Statistical Product and Service Solutions, Armonk, NY, USA).

Statistical analysis

The normality of the variables was tested with the Shapiro Wilk test/Kolmogorov Smirnov tests of Normality. Continuous data were written in the form of mean and standard deviation. Categorical data were reported as counts and percentages. Descriptive statistics estimated mean, standard deviation, and frequency while inferential statistics included chi-square test, logistic regression, Relative Risk (RR), and Attributable Risk (AR). A p-value <0.05 was considered significant. All the statistical tests were two-sided and were performed at a significance level of $\alpha= 0.05$.

Measurement of exposure and outcome

Exposures were measured by assessing exposure on the risk factors including baseline characteristics, comorbidity, tobacco consumption, of the COVID-19 patients retrospectively.

Outcomes were measured by assessing the morbidity outcome in terms of cured or not-cured and the mortality outcome in terms of survivor or non-survivor.

Ethics

The study was conducted by maintaining all kinds of ethical issues in different stages of the study. Ethical clearance was obtained from the Institutional Ethics Committee (IEC) of NIPSOM, Dhaka, Bangladesh. Informed consent was obtained from the participants by informing the purpose and procedure, expected duration, nature, and anticipated physical and psychological risks and benefits of participating. The confidentiality of data and privacy of the participants was strictly maintained. The participants were offered the right to withdraw their consent at any stage of the study. Data were stored into the computer at the central office, NIPSOM under the direct supervision of the principal investigator. Data were used anonymously for the present study only.

Results

Out of 1187 COVID-19 patients, 1016 (85.6%) were enrolled followed by 6.6% had a wrong contact number, 3.5% didn't attend phone calls, 3.3% were unwilling to participate and 1.0% had an incomplete interview -**Figure 1**.

Baseline characteristics of COVID-19 patients

Among 1016 COVID-19 patients, the majority (64.1%) were males 89.9% were aged ≤ 59 years and the median (IQR) age was 37.0 (28-49) years. Of all, 72.6% were married and 39.6% completed their graduation, the majority (32.5%) were service holders and 18.6% were health workforce. More than two-third (69.3%) was from urban settings and around three-fourth (72.7%) was from a nuclear family. The majority (37.0%) had monthly family income between TK.10000-30000 and their average monthly family income was TK.52859(± 51000.37) -**Table 1**.

Comorbidity

More than one third (33.9%) patients had at least 1 comorbidity. Major comorbidities were; DM (35.0%) hypertension (28.4%), COPD (16.6%), CHD (7.8%), chronic liver disease, CLD (2.5%), chronic kidney disease, CKD (4.1%), and malignant diseases (1.8%) -**Figure 2.**

Outcomes of the COVID-19 patients

Morbidity outcomes included 35.6% cured and 64.4% not-cured on the 14th day of the disease while 94.0% cured and 6.0% not-cured on the 28th day. On the contrary, mortality outcomes included 97.7% survivors and 2.3% non-survivors on the 14th day while 97.5% survivors and 2.5% non-survivors on the 28th day -**Figure 3.**

Risk factors associated with outcomes of COVID-19 patients on the 14th day

Regarding morbidity related risk factors, COPD was significantly ($p<0.05$) higher among the not-cured (9.8%) than the cured (5.8%) patients. Regarding mortality related risk factors, elderly (60.9%) and having comorbidity (78.3%) current smokeless tobacco (SLT) use (39.1% Vs. 8.7%), COPD (13.3% Vs, 3.3%), CKD (17.4% Vs. 1.7%), and CLD (13.0% Vs. 1.1%) were significantly ($p<0.01$) higher among the non-survivors than the survivors. On the other hand, DM (39.1% Vs. 16.5%), CHD (17.4% Vs. 4.0%), hypertension (34.8% Vs. 13.8%) and malignant diseases (8.7% Vs, 0.6%) were also significantly ($p<0.05$) higher among the non-survivors than the survivors -**Table 2.**

Risk factors associated with outcomes of COVID-19 patients on the 28th day

Regarding morbidity associated risk factors, the elderly (24.6% Vs. 9.2%) were significantly ($p<0.01$) higher among the not-cured than the cured patients. Having comorbidity (45.9% Vs. 33.1%), current SLT use (9.8% Vs. 3.6%), CKD (6.6% Vs. 1.8%) and CLD (4.9% Vs. 1.0%) were also significantly ($p<0.05$) higher among the not-cured than the cured patients. COPD

(19.7% Vs. 7.6%), CKD (6.6% Vs. 1.8%) CLD (4.9% Vs. 1.0%) were also significantly higher among the not-cured than the cured patients ($p < 0.05$). Regarding mortality associated risk factors, the elderly (56.0% Vs. 2.8%) and having comorbidity (88.0% Vs. 22.2%) were significantly higher among the non-survivors than the survivors ($p < 0.01$). DM (36.0% Vs. 11.1%), hypertension (36.0% Vs. 8.3%) and CKD (16.0% Vs. 0.0%) were also significantly higher among the non-survivors than the survivors ($p < 0.05$) -**Table 3**.

Logistic regression analysis revealed that the risk of 'not-cured' (morbidity) was significantly higher ($p < 0.05$) among the elderly (AOR:2.56, 95% CI:1.31–4.99), patients with comorbidity (OR:1.72, 95% CI:1.02–2.89) and current SLT users (OR:2.95, 95% CI:1.19–7.34) on the 28th day. The risk of 'non-survivor' (mortality) was significantly ($p < 0.01$) higher in the elderly (AOR: 10.14, 95% CI: 3.98-25.79) and patients having comorbidity (AOR: 4.32, 95% CI: 1.49-12.60) on the 14th day. On the contrary, the risk of being non-survivor outcome was significantly higher among the elderly (AOR: 24.37, 95% CI: 2.59-229.37) and patients with comorbidity (AOR: 7.91, 95% CI: 1.91-32.70) -**Table 4**.

Relative Risk and Attributable Risk of outcomes of COVID-19 patients

The risk of 'not-cured' outcome was higher (RR:1.19, AR:11.92%) among the patients with COPD on the 14th day while it was higher among the elderly (RR:2.89, AR:9.52%) and patients with comorbidity (RR:1.66, AR: 3.23%), current SLT users (RR=2.66, AR: 9.36%), CKD (RR:3.33, AR:3.32%), CLD (RR:3.99, AR:17.29%) and COPD (RR:2.68, AR:8.85%) on the 28th day. The risk of 'non-survivor' outcome was higher among the elderly (RR:13.63, AR:19.36%), patients with comorbidity (RR:6.86, AR: 6.83%), current SLT users (RR=3.94, AR:9.33%), DM (RR:3.08, AR:5.38%), CHD (RR:4.54, AR:10.75%), hypertension (RR:3.14, AR:5.74%), CKD (RR:8.97, AR:23.69%), CLD (RR:9.66, AR:26.89%) and malignant diseases (RR:10.29,

AR:30.09%) on the 14th day while it was also higher among the elderly (RR:3.90, AR:69.42%), patients with comorbidity (RR:4.71, AR:56.28%), DM (RR:2.08, AR:35.90%), hypertension (RR:2.30, AR:42.35%) and CKD (RR:2.71, AR:63.16) on the 28th day -**Table 5**.

Discussion

This single centered retrospective cohort study was conducted to identify the risk factors associated with the outcomes of COVID-19 patients on the 14th day and the 28th day of the disease course. The study results on morbidity and mortality associated risk factors including age, comorbidity, and tobacco consumption propose decisive academic, policy, preventive, promotive, and curative strategies and interventions to combat the COVID-19 impact.

Strength and weakness of the study

The current study is the pioneering initiative for the first time done in Bangladesh on the risk factors associated with outcomes of COVID-19 patients. This observational retrospective cohort design was scientifically apposite and feasible for identifying multiple risk factors at a single attempt. The sample size was large enough to draw a valid inference on the risk factors linked with the outcomes of COVID-19 patients considering both morbidity and mortality consequences. Though the study results might not reflect the scenario of the whole country, it offers an impression on the problem under the study with an urban-rural mix and representation of the population of the COVID-19 patients. Despite a few limitations of recall bias that emerged through a telephone-interview and wrong telephone contact number, the study findings conserve irrefutable policy implications for prevention and control of the worst outcomes of the COVID-19 patients.

Baseline characteristics

Though the males (64.1%) have a reasonably higher risk of being affected by COVID-19 than their counterpart females (35.9%), but no significant gender difference of outcomes was revealed in our study. Similar findings were also found by other studies [7-8, 12-13] where males were being affected more than females. It is evident that the males are more involved in outdoor activities in our context and thus they are more vulnerable than the females. Though the majority (89.9%) of the patients were aged ≤ 59 years, the adverse outcomes were more prevalent among elderly patients (≥ 60 years). Urban prevalence (69.3%) was higher than the rural; it could be argued that unplanned urbanization, higher population density, and industrialization in the urban areas increase disease transmission and prevalence. Moreover, more aware urban people undergo laboratory tests for COVID-19 more than the rural people. By occupation, lion shareholders were service holders (32.5%) and health workforce (18.6%). It is evident that the service holders including bankers, security forces, police, and community forces provide various emergency services and are exposed to COVID-19 infection. The health workforce including doctors, nurses, and supporting staff are more vulnerable for the COVID-19 as they have to provide healthcare in direct contact with the patients. Besides, poor quality and quantity of personal protective equipment (PPE) also aggravate their vulnerability for the disease.

Comorbidity and outcomes of COVID-19 patients

Of all, 33.9% patients had diverse comorbidities including DM (35.0%), hypertension (28.4%), COPD (16.6%), and CHD (7.8%). Another study conducted in Wuhan, China [8] also identified DM, hypertension, COPD, and CHD as major comorbidities with the COVID-19 patients. A large difference (64.4% Vs. 6.0%) of morbidity outcome (not-cured) while a small difference (2.3% and 2.5%) of mortality outcome was revealed between the 14th and 28th day of the disease

course respectively. It reflects that the worst mortality outcome occurs within the first 14 days while most of the patients come round by the second 14 days of the disease. So, patient management for the first 14 days must be emphasized and prioritized considering associated risk factors to reduce the morbidity and mortality burden of COVID-19. A study conducted in China revealed different findings, where the death rate was 3.6% among Chinese patients and 1.5% among patients outside China [14]. This discrepancy demands comprehensive comparative studies, but it may be the result of differences in host factors like body immunity, comorbidity, food habit, etc. and agent factors like genomes, virulence, transmission probability, etc. between the geographies.

Risk factors associated with morbidity outcome

COPD (RR=1.19, AR%=11.92) and elderly (AOR=2.56, RR=2.89) were significantly associated with the 'not-cured' morbidity outcome on the 14th and 28th day of the disease. Other relevant studies [12, 15] showed similar findings in respect of age, COPD, and morbidity outcomes. It is established that poor body immunity of the elderly patients instigates the worse progression and adverse outcomes of the COVID-19. Current SLT use (OR=2.96, RR=2.66), CKD (RR=3.33), and CLD (RR=3.99) were found independently associated with morbidity ('not-cured') outcome of COVID-19 on the 28th day. It could be explained by the fact that comorbidity increases the severity of COVID-19 and prolong the morbid condition.

Risk factors associated with mortality outcome

Elderly (AOR=10.14, RR=13.63) and having comorbidity (AOR=4.33, RR=6.86) were significantly associated with the mortality outcome of COVID-19 on the 14th day of the disease. A study conducted in Wuhan, China [8] also showed similar findings. Though the majority of the patients of our study were in the middle age group, the mortality rate was higher among the

elderly. It can be justified by the fact that compromised body immunity of the elderly patients having comorbidity could not win the fight with COVID-19 rather confront the worst outcome. Mortality outcome (non-survivor/death) was also significantly associated with COPD (RR=5.93), DM (RR=3.08), CHD (RR=4.54), hypertension (RR=3.14), CKD (RR=8.97), CLD (RR=9.66), and malignant diseases (RR=10.29) on the 14th day. It is recognized that all the comorbidities weaken the immune system of the patients and aggravate the worst mortality outcome. Though current smoking didn't show any significant association with the morbidity and mortality outcomes and current SLT use was independently associated with the mortality on the 14th day of the disease (OR=4.36, RR=3.94). It is reported that 27.5% adult people (26.9 % men, 28.1% women) of Bangladesh take 'zarda', 'khoinee', 'gul', 'sadapata', 'nossi', etc., which are local smokeless tobacco products [16]. It is argued that smokeless tobacco induces pathophysiological changes in the upper respiratory tract, which makes the virus more progressive and aggressive to aggravate acute respiratory distress syndrome and mortality. Further intensive research and analysis could be conducted to establish the scientific arguments on this association in the Indian sub-continent including Bangladesh.

On the 28th day, mortality outcome was significantly associated with the elderly (AOR=24.367, RR=3.90) and having comorbidity (AOR=7.908, RR=4.71). Another retrospective study conducted in Wuhan; China [8] also revealed that higher median age (69.0 years) of the non-survivors than the survivors (52.0 years). The study also found comorbidity more in the non-survivors (67%) than the survivors (40%). Mortality outcome was also significantly associated with COPD (RR=2.72), DM (RR=2.08), hypertension (RR=2.30), and CKD (RR=2.71). These findings were consistent with other relevant studies conducted in different countries [8,12,14]. It

is claimed that the comorbidity deteriorates the defensive mechanism of the patients and worsen the mortality outcome of COVID-19 patients.

Policy and public health implications

The identified risk factors associated with the outcomes of the COVID-19 patients conserve crucial policy implications for prevention and control of the morbidity and mortality burden of the disease. The study results could contribute to strengthen and reorganize the health care delivery system of the country for providing need-oriented and prioritized services to COVID-19 patients emphasizing the first fourteen days of the disease. The study findings could also contribute to devising effective strategies for the provision of comprehensive health care to COVID-19 patients with comorbidity. Policymakers, health care managers, and relevant stakeholders may use the study findings to revise the national treatment guidelines considering the risk factors, adverse outcomes, and disease course of the COVID-19.

Acknowledgments: The authors are indebted to all the staff of the central laboratory of NIPSOM for their technical assistance in data generation. We are also obliged to all the COVID-19 patients and their families for participating in the study.

Financial support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest: The authors have none to declare

Data availability statement: The data for the study is available by contacting the corresponding author upon request.

References

1. **World Health Organization.** Clinical Management of COVID-19: interim guidance, WHO; 27 May 2020.
2. **Zu ZY, et al.** Coronavirus disease 2019 (COVID-19): a perspective from china. *Radiology*, August 2020; 296: E15–E25 doi: <https://doi.org/10.1148/radiol.2020200490>
3. **Rahman A, Sathi NJ.** Risk factors of the severity of COVID-19: A meta-analysis. doi: <https://doi.org/10.1101/2020.04.30.20086744>.
4. **Jones L, et al.** The COVID-19 pandemic: Important considerations for contact lens practitioners. *Contact Lens and Anterior Eye*, 6 April 2020; 43:196-203. Doi: <https://doi.org/10.1016/j.clae.2020.03.012>
5. **Worldometer.** Reported Cases and Deaths by Country, Territory or Conveyance. (<https://www.worldometers.info/coronavirus/>). Accessed 11 August 2020.
6. **Rothan HA, Byrareddy SN.** The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*, 26 February 2020. Doi: <https://doi.org/10.1016/j.jaut.2020.102433>
7. **Zhang JJ, et al.** Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*, 18 February 2020; 00:1-12.
8. **Zhou F, et al.** Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *THE LANCET*, 2020; 395: 1054–1062. Doi: <https://doi.org/10.1016/>
9. **Guan WJ, et al.** Clinical characteristics of coronavirus disease 2019 in China. *The N Engl J Med*, 2020; 382:1708-1720.

10. **Vardavas CI, Nikitara K.** COVID-19 and smoking: A systematic review of the evidence (Editorial). *Tobacco induced diseases (TID)*, 20 march 2020. Doi: <https://doi.org/10.18332/tid/119324>
11. **Mehra MR, et al.** Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *The N Engl J Med*, 18 June 2020; 382: e102 (1-7).
12. **Yang X, et al.** Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respir Med*. May 2020; 8:475-481. Doi: <https://doi.org/10.1016/>
13. **Grasselli G, et al.** Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. April 2020; 323:1574-1581. doi:10.1001/jama.2020.5394
14. **Baud D, et al.** Real estimates of mortality following COVID-19 infection. *The Lancet Infectious Diseases*, March 12, 2020. Doi: [https://doi.org/10.1016/S1473-3099\(20\)30195-X](https://doi.org/10.1016/S1473-3099(20)30195-X).
15. **Lusignan SD, et al.** Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *The Lancet Infectious Diseases*, May 2020;1-9.
16. **National Institute of Preventive and Social Medicine (NIPSOM).** Ministry of Health and Family Welfare, the Government of Bangladesh. National STEPS Survey for Non-communicable Diseases Risk Factors in Bangladesh. Report on STEPS in Bangladesh 2018; 38.www.nipsom.gov.bd.

Table 1. Distribution of the COVID-19 patients by baseline characteristics

	Baseline characteristic	n (%)	Statistics
Age (Years)	≤59	913 (89.9)	Median (IQR): 37.0 (28-49)
	≥60	103 (10.1)	
Sex	Male	651 (64.1)	
	Female	365 (35.9)	
Marital status	Married	738 (72.6)	
	Unmarried	236 (23.2)	
	Widow/widower/Divorced	42 (4.1)	
Education	Pre-school and Illiterate	78 (7.7)	
	Primary	106 (10.4)	
	Secondary	238 (23.4)	
	Higher secondary	192 (18.9)	
	Graduation and above	402 (39.6)	
Occupation	Housewife	158 (15.6)	
	Service	330 (32.5)	
	Business	142 (14.0)	
	Healthcare worker	189 (18.6)	
	Student	104 (10.2)	
	Retired/unemployed	76 (7.5)	
	Agriculture worker & day labor	17 (1.7)	
Place of residence	Rural	312 (30.7)	
	Urban	704 (69.3)	

Type of family	Nuclear	739 (72.7)	
	Joint	277 (27.3)	
Monthly family	<10000	72 (7.1)	
income (TK.)	10,000 – 30,000	376 (37.0)	Mean (\pm SD):
	31,000 – 50,000	264 (26.0)	52859
	51,000 – 1,000,00	221 (21.8)	(\pm 51000.37)
	> 1,000,00	83 (8.2)	

TK.: Taka, Currency of Bangladesh; n: Number; SD: Standard deviation

Table-2: Risk factors associated with outcomes of the COVID-19 patients (On the 14th day)

Risk factors	Morbidity outcome (n=1016)		ρ - value (95% CI)	Mortality outcome (n=654)		ρ - value (95% CI)	
	Cured	Not cured		Survivors	Non-survivors		
	n (%)	n (%)	n (%)	n (%)			
Age (Years)	≤59	326 (90.1)	0.879*	578 (91.6)	09 (39.1)	< 0.01*	
	≥60	36 (9.9)		67 (10.2)	53 (8.4)		14 (60.9)
Sex	Male	233 (64.4)	0.886*	400 (63.4)	18 (78.3)	0.145*	
	Female	129 (35.6)		236 (36.1)	231 (36.6)		05 (21.7)
Residence	Rural	101 (27.9)	0.149*	204 (32.3)	07 (30.4)	0.849*	
	Urban	261 (72.1)		443 (67.7)	427 (67.7)		16 (69.6)
Having comorbidity		119 (32.9)	0.621*	207 (32.8)	18 (78.3)	< 0.01*	
Current tobacco user		79 (21.8)	106 (16.2)	<0.05*	103 (16.3)	3 (13.0)	1.000**
Current SLT user		16 (4.4)	24 (3.7)	0.556*	21 (3.3)	3 (13.0)	<0.05**
COPD		21 (5.8)	64 (9.8)	<0.05*	55 (8.7)	09 (39.1)	<0.01**
DM		66 (18.2)	113 (17.3)	0.702*	104 (16.5)	9 (39.1)	< 0.05**
CHD		11 (3.0)	29 (4.4)	0.273*	25 (4.0)	04 (17.4)	< 0.05**
HTN		50 (13.8)	95 (14.5)	0.755*	87 (13.8)	08 (34.8)	< 0.05**
CKD		06 (1.7)	15 (2.3)	0.495*	11 (1.7)	04 (17.4)	< 0.01**
CLD		03 (0.8)	10 (1.5)	0.400**	7 (1.1)	03 (13.0)	< 0.01**
Malignant diseases		03 (0.8)	06 (0.9)	1.000**	4 (0.6)	02 (8.7)	< 0.05**
Pregnancy		03 (0.8)	06 (0.9)	1.000**	6 (1.0)	00 (0.0)	1.000**
Hormonal diseases		01 (0.3)	09 (1.4)	0.107**	9 (1.4)	00 (0.0)	1.000**

n: Number; %: Percentage; $p < 0.05$: Significant; CI: Confidence interval; χ^2 -test; ** Fisher`s exact test; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; CHD: Coronary heart disease; HTN: Hypertension; CKD: Chronic kidney disease CLD: Chronic liver disease.

Table-3: Risk factors associated with outcomes of the COVID-19 patients (On the 28th day)

Risk factors	Morbidity outcome		ρ - value (95% CI)	Mortality outcome (n=61)		ρ - value (95% CI)	
	(n=1016)			Survivors	Non-survivors		
	Cured	Not cured	n (%)	n (%)	n (%)	n (%)	
Age (Years)	≤ 59	867 (90.8)	46 (75.4)	< 0.01*	35 (97.2)	11 (44.0)	< 0.01**
	≥ 60	88 (9.2)	15 (24.6)		01 (2.8)	14 (56.0)	
Sex	Male	609 (63.8)	42 (68.9)	0.422*	23 (63.9)	19 (76.0)	0.315*
	Female	346 (36.2)	19 (31.1)		13 (36.1)	06 (24.0)	
Residence	Rural	290 (30.4)	22 (36.1)	0.350*	14 (38.9)	08 (32.0)	0.582**
	Urban	665 (69.6)	39 (63.9)		22 (61.1)	17 (68.0)	
Having comorbidity		316 (33.1)	28 (45.9)	< 0.05*	08 (22.2)	20 (80.0)	< 0.01*
Current tobacco user		173 (18.1)	12 (19.7)	0.760*	8 (22.2)	4 (16.0)	0.745**
Current SLT user		34 (3.6)	6 (9.8)	< 0.05**	3 (8.3)	3 (12.0)	0.682**
COPD		73 (7.6)	12 (19.7)	< 0.01*	02 (5.6)	10 (40.0)	< 0.01**
DM		166 (17.4)	13 (21.3)	0.435*	4 (11.1)	09 (36.0)	< 0.05*
CHD		35 (3.7)	05 (8.2)	0.086**	01 (2.8)	04 (16.0)	0.149**
HTN		133 (13.9)	12 (19.7)	0.214*	03 (8.3)	09 (36.0)	< 0.05**
CKD		17 (1.8)	04 (6.6)	< 0.05**	00 (0.0)	04 (16.0)	< 0.05**
CLD		10 (1.0)	03 (4.9)	< 0.05**	00 (0.0)	03 (12.0)	0.064**
Malignant diseases		07 (0.7)	02 (3.3)	0.097**	00 (0.0)	02 (8.0)	0.164**
Pregnancy		08 (0.8)	01 (1.6)	0.429**	01 (2.8)	00 (0.0)	1.000**
Hormonal diseases		09 (0.9)	01 (1.6)	0.463**	00 (0.0)	01 (4.0)	0.410**

n: Number; %: Percentage; $p < 0.05$: Significant; CI: Confidence interval; χ^2 -test; ** Fisher`s exact test; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; CHD: Coronary heart disease; HTN: Hypertension; CKD: Chronic kidney disease CLD: Chronic liver disease.

Table-4: Logistic regression analysis of the risk factors associated with morbidity (Not-cured) and mortality (non-survivor) outcomes of COVID-19 patients

Risk factors	Unadjusted model			Adjusted model		
	OR	95% CI	<i>p-value</i>	AOR	95% CI	<i>p-value</i>
Risk factors associated with morbidity outcome (not-cured)						
On the 28 th day	Age					
	≤59	Reference		Reference		
	≥60	3.213	(1.72-5.99)	0.000	2.559	(1.31-4.99) <0.01
	Having comorbidity					
	No	Reference		Reference		
	Yes	1.716	(1.02-2.89)	0.042	1.431	(0.83-2.47) 0.198
	Current SLT use					
	No	Reference		Reference		
	Yes	2.955	(1.19-7.34)	0.020	2.168	(0.84-5.61) 0.110
Risk factors associated with mortality outcome (non-survivor)						
On the 14 th day	Age (Years)					
	≤59	Reference		Reference		
	≥60	16.964	(7.01-41.04)	0.000	10.136	(3.98-25.79) <0.01
	Having comorbidity					
	No	Reference		Reference		
	Yes	7.374	(2.70-20.14)	0.000	4.326	(1.49-12.60) <0.01
	Current SLT use					
	No	Reference		Reference		

	Yes	4.357	(1.20-15.81)	0.025	2.253	(0.53-9.61)	0.273
On the 28 th day	Age (Years)						
	≤59	Reference			Reference		
	≥60	44.454	(5.25-378.19)	0.001	24.367	(2.59-229.37)	<0.01
	Having comorbidity						
	No	Reference			Reference		
	Yes	14.000	(3.99-49.16)	0.000	7.908	(1.91-32.70)	<0.01

CI: Confidence interval; OR: Odds Ratio; AOR: Adjusted Odds Ratio; SLT: Smokeless tobacco

Table-5: Relative Risk and Attributable Risk of morbidity (Not-cured) and mortality (non-survivor) outcomes of COVID-19 patients by selected risk factors

	Risk factors	RR	AR%
Risk factors linked with morbidity outcome (not-cured)			
On the 14 th day	COPD/lung disease	1.19	11.92
On the 28 th day	Age (≥ 60 years)	2.89	9.52
	Having comorbidity	1.66	3.23
	Current SLT use	2.66	9.36
	COPD/lung disease	2.68	8.85
	CKD	3.33	13.32
	CLD	3.99	17.29
Risk factors linked with mortality outcome (non-survivor)			
On the 14 th day	Age (≥ 60 years)	13.63	19.36
	Having comorbidity	6.86	06.83
	Current SLT use	3.94	09.33
	COPD/lung disease	5.93	11.69
	DM	3.08	05.38
	CHD	4.54	10.75
	HTN	3.14	05.74
	CKD	8.97	23.69
	CLD	9.66	26.89
	Malignant disease	10.29	30.09
On the 28 th day	Age (≥ 60 years)	3.90	69.42

Having comorbidity	4.71	56.28
COPD/lung disease	2.72	52.72
DM	2.08	35.90
HTN	2.30	42.35
CKD	2.71	63.16

RR: Relative risk; AR: Attributable risk; SLT: Smokeless tobacco; DM: Diabetes mellitus; CHD: Coronary heart diseases; HTN: Hypertension; CKD: Chronic kidney diseases; CLD: Chronic liver diseases.



Fig. 1. The flowchart of the 2014-2015 National Survey of Children's Health (NSCH) process.



Figure 1: Number of Respondents by Gender and Age Group



Figure 10: Percentage distribution of respondents by gender across categories